MingSight Pharma in licensing pact with Pfizer
As per the terms of the agreement, Pfizer is expected to get upfront fee by MingSight which it will pay in the form of cash and a convertible
miRecule has signed a research collaboration with EM subsidiary Rio Biofarma Brasil (RBBL) to co-develop peptide-mediated delivery technologies aimed at improving targeted ribonucleic acid (RNA) therapeutics delivery to tissues beyond the liver and muscles in a range of disease areas.
AstraZeneca and Pozen have co-developed Vimovo, which is a fixed-dose combination of enteric-coated naproxen, a pain-relieving NSAID and immediate-release esomeprazole, a proton pump inhibitor (PPI). Vimovo is indicated